<DOC>
	<DOC>NCT02913105</DOC>
	<brief_summary>The purpose of the present study is to assess the effects of LMB763 with respect to safety, tolerability, and on markers of liver inflammation in patients with NASH</brief_summary>
	<brief_title>Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH</brief_title>
	<detailed_description />
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>Male/female patients, 18 years or older Written informed consent Presence of NASH by histologic evidence (liver biopsy) and elevated alanine aminotransferase (ALT), OR phenotypic diagnosis of NASH based on elevated ALT, BMI and diagnosis of Type 2 diabetes mellitus Current use of obeticholic acid (OCA) New initiation GLP1 agonists such as liraglutide, exenatide , lixisenatide, albiglutide or dulaglutide within 3 months of screening Pregnant or nursing (lactating) women Women of childbearing potential, unless they are using highly effective methods of contraception during dosing and for 5 days after stopping study medication Current or history of significant alcohol consumption for a period of more than 3 consecutive months within 1 year prior to screening Clinical evidence of hepatic decompensation or severe liver impairment Previous diagnosis of other forms of chronic liver disease Uncontrolled diabetes mellitus History or current diagnosis of ECG abnormalities Patients with contraindications to MRI imaging</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Non-alcoholic Steatohepatitis</keyword>
	<keyword>NASH</keyword>
	<keyword>Fatty liver disease</keyword>
</DOC>